Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis

Summary

This study is a double-blind, randomized, multisite, placebo-controlled trial comparing the safety and efficacy of TQ versus placebo in patients hospitalized for babesiosis with low risk for relapsing disease who will also be administered a standard-of-care antimicrobial regimen (A/A) that is recommended in the 2020 IDSA guideline on the diagnosis and management of babesiosis.

Timeline

Start

2024-06-17

Primary completion

2027-03-01

Completion

2027-07-01

Drugs

Indications